American Society of Hematology

Figure 5.

$Platelet clearance and resting platelet activation markers. Flow cytometry analysis for WT, RGS18−/−, RGS10−/−, and RGS10−/−18−/− mice to measure clearance of anti-GPIbβ:DyLight488 in vivo–labeled platelets over the course of 96 hours (A). At baseline and every 24 hours thereafter, platelets were identified using anti-CD41 (αIIb integrin) and then analyzed for DyLight488+ by flow cytometry. *P ≤ .05 for WT vs RGS10−/−18−/−. n = 5; mean ± SEM. (B) Relative fraction of platelets that were positive for both anti-CD41 and TO. n = 9; mean ± SEM. Binding of Jon/A (C,E) and anti-TLT-1 (D) to resting (C-D) or 10 μM epinephrine–stimulated (E) platelets. n = 6; mean ± SEM.$

Platelet clearance and resting platelet activation markers. Flow cytometry analysis for WT, RGS18^−/−, RGS10^−/−, and RGS10^−/−18^−/− mice to measure clearance of anti-GPIbβ:DyLight488 in vivo–labeled platelets over the course of 96 hours (A). At baseline and every 24 hours thereafter, platelets were identified using anti-CD41 (α_IIb integrin) and then analyzed for DyLight488⁺ by flow cytometry. *P ≤ .05 for WT vs RGS10^−/−18^−/−. n = 5; mean ± SEM. (B) Relative fraction of platelets that were positive for both anti-CD41 and TO. n = 9; mean ± SEM. Binding of Jon/A (C,E) and anti-TLT-1 (D) to resting (C-D) or 10 μM epinephrine–stimulated (E) platelets. n = 6; mean ± SEM.

This Feature Is Available To Subscribers Only